Travere Therapeutics, Inc. (TVTX) experienced a significant after-hours plunge of 5.09% following the release of its fourth quarter and full year 2025 financial results.

The stock's decline appears to be driven by investor reaction to the company's earnings report, which showed strong revenue growth but also revealed an operating loss and a substantial increase in selling, general, and administrative expenses. Additionally, a regulatory filing disclosed that the company's Chief Legal Officer disposed of common shares, which may have contributed to negative sentiment.

Despite reporting a net income of $2.7 million for the quarter and impressive 108% year-over-year growth in U.S. net product sales for its drug FILSPARI, the company posted an operating loss of $32.4 million. The significant rise in SG&A expenses to $101.7 million, attributed to investments for a potential product launch and increased commercialization costs, likely weighed on investor confidence during the after-hours session.